Ruperto N. et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Diss 2018; 77: 1710-1719
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.